PharmacyCodes



Escitalopram [Inn] en es it fr

Escitalopram [Inn] Brand names, Escitalopram [Inn] Analogs

Escitalopram [Inn] Brand Names Mixture

  • No information avaliable

Escitalopram [Inn] Chemical_Formula

C20H21FN2O

Escitalopram [Inn] RX_link

http://www.rxlist.com/cgi/generic/lexapro.htm

Escitalopram [Inn] fda sheet

Escitalopram_[Inn] FDA

Escitalopram [Inn] msds (material safety sheet)

Escitalopram [Inn] Synthesis Reference

No information avaliable

Escitalopram [Inn] Molecular Weight

324.392 g/mol

Escitalopram [Inn] Melting Point

No information avaliable

Escitalopram [Inn] H2O Solubility

No information avaliable

Escitalopram [Inn] State

Solid

Escitalopram [Inn] LogP

4.222

Escitalopram [Inn] Dosage Forms

Tablet

Escitalopram [Inn] Indication

For the treatment of major depressive disorder and Generalized Anxiety Disorder (GAD).

Escitalopram [Inn] Pharmacology

Escitalopram is one of a class of antidepressants known as selective serotonin reuptake inhibitors (SSRIs). It is used to treat the depression associated with mood disorders. It is also used on occassion in the treatment of body dysmorphic disorder and anxiety. The antidepressant, antiobsessive-compulsive, and antibulimic actions of escitalopram are presumed to be linked to its inhibition of CNS neuronal uptake of serotonin. In vitro studies show that escitalopram is a potent and selective inhibitor of neuronal serotonin reuptake and has only very weak effects on norepinephrine and dopamine neuronal reuptake. Escitalopram has no significant affinity for adrenergic (alpha1, alpha2, beta), cholinergic, GABA, dopaminergic, histaminergic, serotonergic (5HT1A, 5HT1B, 5HT2), or benzodiazepine receptors; antagonism of such receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects for other psychotropic drugs. The chronic administration of escitalopram was found to downregulate brain norepinephrine receptors, as has been observed with other drugs effective in the treatment of major depressive disorder. Escitalopram does not inhibit monoamine oxidase.

Escitalopram [Inn] Absorption

The absolute bioavailability of citalopram is about 80% relative to an intravenous dose

Escitalopram [Inn] side effects and Toxicity

Signs of overdose include convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation).

Escitalopram [Inn] Patient Information

Escitalopram [Inn] Organisms Affected

Humans and other mammals